20240033341. HIV VACCINE IMMUNOGENS simplified abstract (California Institute of Technology)

From WikiPatents
Jump to navigation Jump to search

HIV VACCINE IMMUNOGENS

Organization Name

California Institute of Technology

Inventor(s)

Harry Gristick of Pasadena CA (US)

Pamela J. Bjorkman of Altadena CA (US)

Harald Hartweger of New York NY (US)

Michel C. Nussenzweig of New York NY (US)

HIV VACCINE IMMUNOGENS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240033341 titled 'HIV VACCINE IMMUNOGENS

Simplified Explanation

The abstract of this patent application describes the invention of HIV immunogens and their use in generating an immune response in a subject. It also discloses a method for treating or preventing HIV infection in a subject using these HIV immunogens or antibodies generated by the disclosed methods.

  • The patent application describes HIV immunogens and their use in generating an immune response in a subject.
  • The disclosed method can be used for treating or preventing HIV infection in a subject.
  • The invention includes the use of HIV immunogens or antibodies generated by the disclosed methods.

Potential Applications

  • Treatment of HIV infection: The disclosed HIV immunogens and antibodies can be used as a potential treatment for HIV infection in humans.
  • Prevention of HIV infection: The disclosed method can be used to develop vaccines or immunotherapies for preventing HIV infection in individuals at risk.

Problems Solved

  • Lack of effective HIV treatments: The invention addresses the problem of limited treatment options for HIV infection by providing a novel approach using HIV immunogens and antibodies.
  • Limited prevention strategies: The disclosed method offers a new avenue for developing preventive measures against HIV infection, which is crucial in regions with high HIV prevalence.

Benefits

  • Enhanced immune response: The HIV immunogens and antibodies generated by the disclosed methods can stimulate a robust immune response in individuals, potentially leading to better control of HIV infection.
  • Versatile application: The disclosed method can be used in various settings, including both therapeutic and preventive approaches, providing flexibility in addressing different stages of HIV infection.


Original Abstract Submitted

provided herein are hiv immunogens and uses thereof for generating an immune response in a subject. this disclosure further provides a method for treating or preventing a human immunodeficiency type i (hiv-i) infection in a subject using the disclosed hiv immunogens and/or antibodies generated by any of the methods disclosed herein.